FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3188920199> ?p ?o ?g. }

• W3188920199 endingPage "2990" @default.
• W3188920199 startingPage "2979" @default.
• W3188920199 abstract "The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS).In this randomized European phase II trial, patients age 0.5-50 years received 21-day cycles combining vincristine (1.5 mg/m2 once a day on day 1 and day 8) and irinotecan (50 mg/m2 once a day from day 1 to day 5) with and without temozolomide (125 mg/m2 once a day from day 1 to day 5 and 150 mg/m2 once a day from cycle 2), until progression or unacceptable toxicity. The primary end point was objective response rate after two cycles. Secondary end points included best response, progression-free survival, overall survival, and adverse events. A Simon 2-stage design was initially planned to separately analyze 40 patients/arm. After amendment, the trial sample size was increased to 120 and a comparison between arms, adjusted for confounding factors, was added to the statistical plan (ClinicalTrials.gov, NCT01355445).Overall, 120 patients (60 per arm) were recruited in 37 European centers. The median age was 11 years (range, 0.75-45); 89% of patients had a relapsed RMS. The objective response rate was 44% (24 of 55 evaluable patients) for VIT versus 31% (18 of 58) for VI (adjusted odds ratio, 0.50; 95% CI, 0.22 to 1.12; P = .09). The VIT arm achieved significantly better overall survival (adjusted hazard ratio, 0.55; 95% CI, 0.35 to 0.84; P = .006) compared with VI, with consistent progression-free survival results (adj-hazard ratio, 0.68; 95% CI, 0.46 to 1.01; P = .059). Overall, patients experienced adverse events ≥ grade 3 more frequently with VIT than VI (98% v 78%, respectively; P = .009), including a significant excess of hematologic toxicity (81% v 61%; P = .025).The addition of temozolomide to VI improved chemotherapy efficacy for patients with relapsed RMS, with manageable increase in toxicity. VIT is considered the new standard treatment in these patients in the European paediatric Soft Tissue Sarcoma Group and will be the control arm in the next randomized trial." @default.
• W3188920199 created "2021-08-16" @default.
• W3188920199 creator A5006570922 @default.
• W3188920199 creator A5008870012 @default.
• W3188920199 creator A5008878915 @default.
• W3188920199 creator A5011038897 @default.
• W3188920199 creator A5017189738 @default.
• W3188920199 creator A5018693666 @default.
• W3188920199 creator A5025577967 @default.
• W3188920199 creator A5027348510 @default.
• W3188920199 creator A5039972816 @default.
• W3188920199 creator A5041691224 @default.
• W3188920199 creator A5053499301 @default.
• W3188920199 creator A5061144832 @default.
• W3188920199 creator A5065115707 @default.
• W3188920199 creator A5072160244 @default.
• W3188920199 creator A5073202790 @default.
• W3188920199 creator A5075951287 @default.
• W3188920199 date "2021-09-20" @default.
• W3188920199 modified "2023-10-17" @default.
• W3188920199 title "Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial" @default.
• W3188920199 cites W1972830050 @default.
• W3188920199 cites W2019607817 @default.
• W3188920199 cites W2112772060 @default.
• W3188920199 cites W2113173711 @default.
• W3188920199 cites W2137747512 @default.
• W3188920199 cites W2142190381 @default.
• W3188920199 cites W2149228256 @default.
• W3188920199 cites W2167713837 @default.
• W3188920199 cites W2167805334 @default.
• W3188920199 cites W2740969352 @default.
• W3188920199 cites W2895922290 @default.
• W3188920199 cites W2972537131 @default.
• W3188920199 cites W2975416164 @default.
• W3188920199 doi "https://doi.org/10.1200/jco.21.00124" @default.
• W3188920199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34343032" @default.
• W3188920199 hasPublicationYear "2021" @default.
• W3188920199 type Work @default.
• W3188920199 sameAs 3188920199 @default.
• W3188920199 citedByCount "30" @default.
• W3188920199 countsByYear W31889201992021 @default.
• W3188920199 countsByYear W31889201992022 @default.
• W3188920199 countsByYear W31889201992023 @default.
• W3188920199 crossrefType "journal-article" @default.
• W3188920199 hasAuthorship W3188920199A5006570922 @default.
• W3188920199 hasAuthorship W3188920199A5008870012 @default.
• W3188920199 hasAuthorship W3188920199A5008878915 @default.
• W3188920199 hasAuthorship W3188920199A5011038897 @default.
• W3188920199 hasAuthorship W3188920199A5017189738 @default.
• W3188920199 hasAuthorship W3188920199A5018693666 @default.
• W3188920199 hasAuthorship W3188920199A5025577967 @default.
• W3188920199 hasAuthorship W3188920199A5027348510 @default.
• W3188920199 hasAuthorship W3188920199A5039972816 @default.
• W3188920199 hasAuthorship W3188920199A5041691224 @default.
• W3188920199 hasAuthorship W3188920199A5053499301 @default.
• W3188920199 hasAuthorship W3188920199A5061144832 @default.
• W3188920199 hasAuthorship W3188920199A5065115707 @default.
• W3188920199 hasAuthorship W3188920199A5072160244 @default.
• W3188920199 hasAuthorship W3188920199A5073202790 @default.
• W3188920199 hasAuthorship W3188920199A5075951287 @default.
• W3188920199 hasBestOaLocation W31889201991 @default.
• W3188920199 hasConcept C121608353 @default.
• W3188920199 hasConcept C126322002 @default.
• W3188920199 hasConcept C141071460 @default.
• W3188920199 hasConcept C142724271 @default.
• W3188920199 hasConcept C168563851 @default.
• W3188920199 hasConcept C197934379 @default.
• W3188920199 hasConcept C203092338 @default.
• W3188920199 hasConcept C207103383 @default.
• W3188920199 hasConcept C2776694085 @default.
• W3188920199 hasConcept C2776755627 @default.
• W3188920199 hasConcept C2777389519 @default.
• W3188920199 hasConcept C2778256501 @default.
• W3188920199 hasConcept C2779429289 @default.
• W3188920199 hasConcept C2780259306 @default.
• W3188920199 hasConcept C2780844630 @default.
• W3188920199 hasConcept C31760486 @default.
• W3188920199 hasConcept C44249647 @default.
• W3188920199 hasConcept C526805850 @default.
• W3188920199 hasConcept C535046627 @default.
• W3188920199 hasConcept C71924100 @default.
• W3188920199 hasConceptScore W3188920199C121608353 @default.
• W3188920199 hasConceptScore W3188920199C126322002 @default.
• W3188920199 hasConceptScore W3188920199C141071460 @default.
• W3188920199 hasConceptScore W3188920199C142724271 @default.
• W3188920199 hasConceptScore W3188920199C168563851 @default.
• W3188920199 hasConceptScore W3188920199C197934379 @default.
• W3188920199 hasConceptScore W3188920199C203092338 @default.
• W3188920199 hasConceptScore W3188920199C207103383 @default.
• W3188920199 hasConceptScore W3188920199C2776694085 @default.
• W3188920199 hasConceptScore W3188920199C2776755627 @default.
• W3188920199 hasConceptScore W3188920199C2777389519 @default.
• W3188920199 hasConceptScore W3188920199C2778256501 @default.
• W3188920199 hasConceptScore W3188920199C2779429289 @default.
• W3188920199 hasConceptScore W3188920199C2780259306 @default.
• W3188920199 hasConceptScore W3188920199C2780844630 @default.
• W3188920199 hasConceptScore W3188920199C31760486 @default.
• W3188920199 hasConceptScore W3188920199C44249647 @default.

• next